Frontlight ResearchEarly access
Enrolling by invitationPhase 2
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
Key facts
- Who runs it
- Bryan Cotton
- Where
- Aurora, Houston, Jackson, Miami, and Nashville, United StatesSee the 5 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 314 people, planned
- Started
- 27 Sept 2023
- Expected to end
- Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Thrombate infusion
- Placebo
- Record updated
- 9 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Admission to trauma service
- Polytraumatic injuries OR pelvic/long bone fracture
- Planned admission to trauma ICU or step-down/SIMU setting (this includes STICU, SIMU/TIMU, BICU, and BIMU)
- Informed consent obtained
Who cannot take part
- Known hematologic or immunologic disorders
- Known allergy to Antithrombin or it's components
- Prisoners (defined as those directly admitted from correctional facility)
- Known or suspected pregnancy
- ≥ 20% total body surface area (TBSA) burned
- Nonsurvivable head injuries
- Known prehospital anticoagulant use
- Patients initially placed on unfractionated heparin for thromboprophylaxis
- Enrollment in another interventional study unless approved by Trial Principal Investigator
Where in United States
- University of ColoradoAurora, United StatesEnrolling by invitation
- The University of Texas Health Science Center at HoustonHouston, United StatesEnrolling by invitation
- University of Mississippi Medical CenterJackson, United StatesEnrolling by invitation
- Jackson Memorial Hospital/University of MiamiMiami, United StatesEnrolling by invitation
- Vanderbilt University HospitalNashville, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The purpose of this study is to determine if additional interventions will assist with decreasing the risk and/or severity of thromboembolism (clotting complications) in patients who have experienced a major traumatic event.
The 2 groups in the trial
- Thrombate infusionTreatment being tested
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism (TRAIT)
- Record updated
- 9 October 2026